CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 309 enrolled
Drug / intervention
WC3011 Estradiol Vaginal Creamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01455597
NCT01455597Phase 3Completed
CompareCT.gov

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in the Treatment of Symptoms of Vulvovaginal Atrophy in Postmenopausal Women

Warner Chilcott·interventional·Posted Oct 20, 2011·Updated May 9, 2022

In Brief

A Phase 3 clinical trial evaluating WC3011 Estradiol Vaginal Cream for Vulvovaginal Atrophy. Completed, enrolled 309 participants across 64 sites.

Detailed Summary

This is an open-label extension study evaluating the long-term safety and efficacy of WC3011 in non-hysterectomized, healthy, postmenopausal women with vulvovaginal atrophy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVulvovaginal Atrophy
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 20, 2011
Enrollment StartOct 20, 2011
Primary CompletionDec 3, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.7 years ago

Interventions

WC3011 Estradiol Vaginal Creamdrug

WC3011 estradiol vaginal cream, 3 times a week for 40 weeks.